Trial
NCT04489940
Bintrafusp Alfa in High Mobility Group AT-Hook 2 (HMGA2) Expressing Triple Negative Breast Cancer
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
EMD Serono Research & Development Institute, Inc.
Collaborators
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Condition
Triple Negative Breast Neoplasms
Intervention
Bintrafusp alfa
Why stopped
The study was prematurely discontinued by the sponsor due to probability of success which was too low to justify the continuation of recruitment.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-04-10